UNLOCKING THE POTENTIAL OF THE
IMMUNE SYSTEM WITH A NEW
CLASS OF THERAPEUTICS

Immunophotonics uses a proprietary glycan polymer with
platform potential to stimulate antigen capture and uptake along
with other immunological processes that are intended to trigger an
immune response, thereby enabling the rejection of cancer and other diseases.
Read More

Unlocking the potential
of the immune system
with a new class of
therapeutics

Proprietary glycan polymer with platform potential
stimulates antigen capture, uptake, and
immunological responses.
Intended to stimulate an immune response, thereby
enabling the rejection of cancer and other
diseases.

Practical Applications to Elevate Modern Medicine

Transforming
Interventional
Oncology

Injecting IP-001 following routine tumor ablations may transform this conventional surgical intervention into a systemically active immunotherapy.

Read More

Elevating
Immunotherapy

IP-001 upregulates T-cell activation, downregulates T-cell exhaustion, and drives stronger Th-1 and cytotoxic T-cell response, which could enhance other immunotherapies, such as checkpoint inhibitors.

Read More

Boosting
Vaccines

IP-001 is a powerful immunoadjuvant that enhances antigen-specific immunity against infectious diseases, including SARS-CoV-2, potentially increasing the efficacy of vaccines.

Read More

Immunophotonics is dedicated to developing its proprietary technology for the benefit of global human health. We believe our multimodal approach can elevate modern medicine, allowing everyday-routine treatments to provide enhanced outcomes.

News Highlights

September 12, 2024

Immunophotonics, CIRSE, and Next Research Announce Innovative Phase 2/3 Clinical Trial: INJECTABL-3

Latest News, Press Releases
Immunophotonics is pioneering the field of Interventional Immunology-Oncology™, where a single injection of IP-001 --seamlessly integrated into the clinical workflow--...
Read More
August 15, 2024

Immunophotonics Announces 1st Patient Dosed in a Randomized Phase 2 Study at the University of Louisville

Latest News, Press Releases
We are thrilled to announce that Dr. Robert Martin has successfully enrolled and treated the first patient in our groundbreaking...
Read More
July 16, 2024

Authorization to Proceed Received on Immunophotonics’ INJECTABL-2 Clinical Trial

Latest News, Press Releases
Immunophotonics is excited to announce that a leading academic medical center that combines high-quality complex patient care with innovative scientific...
Read More
1 2 3 … 6